Company / Revenue per Share
Ovid Therapeutics Inc. Revenue per Share History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue per Share
$0.01
FY2025
5-year range
$0.01 / $2.96
FY2022-FY2025
Trend
+43.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Revenue per Share returned to growth in FY2025 after 2 years of decline, reaching $0.01.
Based on SEC 10-K filings.
0.01 in FY2025 with a 3-year CAGR of -86.1%.
Declined from $0.02 to $0.01 over the past 2 years.
Revenue per Share over time
Growth rates
- 3-Year CAGR
- -86.1%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, revenue per share increased 43.7% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.61 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Revenue per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.01 | +43.7% |
| FY2024 | $0.01 | -74.0% |
| FY2023 | $0.02 | -99.3% |
| FY2022 | $2.96 | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026